Press Releases

 
Press Releases
  Date Title and Summary View
Apr 27, 2006
Cranbury, NJ, APRIL 27, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that it has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for AT2101 for th...
PDF
Apr 27, 2006
Cranbury, NJ, APRIL 27, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that it has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for AT2101 for...
PDF
Apr 11, 2006
Cranbury, NJ, April 11, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) has recommended orphan medicinal ...
PDF
Mar 31, 2006
Cranbury, NJ, March 31, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-delivered pharmacological chaperones for the treatment of human genetic diseases, today announced the appointment of Donald J. Hayden, Jr. as executive chairman of the company's Board of Directors. Mr. Hayden brings to Amicus the ...
PDF
Feb 15, 2006
Cranbury, NJ, February 15, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced that AT2101 has received orphan drug designation from the U.S. Food and Drug Administration. AT2101 is an experimental, oral therapy...
PDF
Jan 6, 2006
Cranbury, NJ, January 6, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced that David J. Lockhart, Ph.D. has been appointed chief scientific officer. Dr. Lockhart most recently served as president and chief sc...
PDF
Jan 4, 2006
Cranbury, NJ, January 4, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced that the company will present at the 24th Annual JPMorgan Healthcare Conference. This will be the company's first public presentation ...
PDF
Sep 8, 2005
Cranbury, NJ, September 8, 2005 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced positive results from Phase I clinical studies of its lead compound Amigal™ (migalastat hydrochloride) that is being developed ...
PDF
Sep 8, 2005
Cranbury, NJ, September 8, 2005 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced the closing of a $55 million Series C financing. The company intends to use the proceeds to advance its drug pipeline based on the co...
PDF
Jan 24, 2005
North Brunswick, NJ - Amicus Therapeutics, an emerging biopharmaceutical company, today announced the appointment of John F. Crowley as chairman and CEO. Mr. Crowley was most recently founding president and CEO of Orexigen Therapeutics. Prior to this Mr. Crowley was senior vice president of Genzyme Therapeutics and founding president and CEO of ...
PDF
Page: FirstPrevious ...
33
NextLast